Some folks can view data from early, small clinical trials too skeptically or overly enthusiastically, and maybe that’s going on with some preliminary results from Verve Therapeutics. Good news? Bad news? I’m going to start with two articles about the same news that have very different vibes. What do I think? On the whole, I […]
Weekly reads: Verve Therapeutics, Casgevy UK OK, GDNF, MYC Read More »
Chinese CRISPR research continues to grow and this includes interesting CRISPR biotech firms. Some here in the U.S. worry that American gene editing firms could be lagging behind. Especially over the past year, investors and even some scientists have voiced frustration. U.S. gene editing firms like Editas have been struggling for years. Its stock is
Weekly reads: Chinese CRISPR biotechs, cultured meat war, MSCs for Alzheimer’s Read More »
What are the current FDA-approved cell and gene therapies? How many of those involve true stem cells? Many of us have wished for a more specific list of FDA-approved stem cell therapies. Patients and fellow scientists often asked me about such lists. They even wish for annotated lists. For that reason, I’ve made and kept
Updated 2025 List of FDA-Approved Cell and Gene Therapies Read More »
Did you predict the major events in the stem cell and regenerative medicine field this year? I tried and today’s post are the grades on my predictions. Prediction is a key part of being a scientist even if we may not think about it that much. For instance, we have to try to predict what
Grading my 20 stem cell & regenerative medicine predictions for 2024 Read More »
What was the biggest upbeat regenerative medicine story of 2024? I have my own favorites but decided to run a poll. Just putting the poll together, it was evident that this year was unusually full of good and encouraging news. Diabetes and sickle cell regenerative medicine therapies In The Niche polling, so far Vertex Type
Positive regenerative medicine story of the year: diabetes & sickle cell were tops Read More »
What are the most significant stem cell and regenerative medicine good news stories of 2024? Since it has been an eventful year, there are many possibilities. Please see our poll at the bottom of this post and weigh in on what you think is the most important encouraging news. If you don’t see your choice
Poll on stem cell & regenerative medicine good news of 2024 Read More »
Stem cell hype is a big problem these days. It’s been going on for decades. Even some generally good citizens of the stem cell and regenerative medicine arena engage in it at times. Maybe a few of them don’t even realize what they are doing. I think a few journalists occasionally fall into the hype
Recommended reads: 3 infected in Mexico, stem cell hype, hearing restoration Read More »
Looking for some stem cell good news? You’ll like today’s post. One mission of this blog The Niche is to promote rigorous science-based regenerative medicine, which can lead to investigating and writing about not-so-upbeat stuff. Risky clinics. People getting hurt. Patient lawsuits. Serious FDA, FTC, or state AG regulatory developments. Such actions can be good
Recent stem cell & regenerative medicine good news Read More »
Each year I make predictions for the stem cell and regenerative medicine field for the following year. Today’s prediction post is focused on what to expect in 2024. You can also see my stem cell predictions for 2023 and my grades on how I did. I also have made a video version of these predictions so please
20 stem cell & regenerative medicine predictions for 2024 Read More »
Years ago I wrote about how I wished humans could form a blastema, which is a special area of regeneration near an injury that drives tissue replacement. For example, when a lizard loses its tail to a pursuing bobcat, if it can regrow a new one that process will depend on a blastema. The same goes
New Year’s reads: having a blastema, gene therapy cost, pathogen lab escape data Read More »